Journal
FRONTIERS IN PHYSIOLOGY
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2017.00814
Keywords
lncRNA; GAS5; cancer; prognosis; lymph node metastasis; high tumor stage; meta-analysis
Categories
Funding
- National Key Basic Research Program of China (973 Program) [2014CB745201]
- Chinese High-Tech (863) Program [2014AA020607]
- National Natural Science Foundation of China [81402103]
- International S&T Cooperation program of China (ISTCP) [2014DFA31050]
- National Science Foundation Projects of Guangdong Province [2014A030313717]
- Shenzhen Municipal Government of China [ZDSYS201504301722174, JCYJ20150330102720130, GJHZ20150316154912494]
- Special Support Funds of Shenzhen for Introduced High-Level Medical Team
Ask authors/readers for more resources
The growth arrest-specific transcript 5 (GAS5) is a long noncoding RNA with low expression in multiple cancers. This meta-analysis aims to explore the association between GAS5 expression levels and cancer patients' prognosis. We collected all the relevant literatures about GAS5 expression levels associated with overall survival (OS), lymph node metastasis (LNM) and high tumor stage (II/III/IV) (HTS) from the PubMed and Web of Science. The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were calculated to evaluate the link strength between GAS5 and cancer prognosis. A total of 934 patients from 14 studies were included to the present meta-analysis, according to the inclusion and exclusion criteria. The results demonstrated that low expression of GAS5 could predict poor OS in cancer patients (HR = 1.955, 95% CI: 1.551-2.465, P < 0.001). Meanwhile we also analyzed the following cancers independently: hepatocellular carcinoma (HR = 1.893, 95% CI: 1.103-3.249, P = 0.021) and urothelial carcinoma (HR = 1.653, 95% CI: 1.185-2.306, P = 0.003). Compared to the high GAS5 expression group, additionally, patients with low GAS5 expression in tumor tissues were more prone to lymph node metastasis (OR = 0.234, 95% CI: 0.153-0.358, P < 0.001) and high tumor stage (OR = 0.185, 95% CI: 0.102-0.333, P < 0.001). In conclusion, this meta-analysis showed that GAS5 might be served as a novel biomarker for predicting prognosis in various types of cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available